PHENOTYPIC SUSCEPTIBILITY TO VRCO7-523LS AND ITS CORRELATES IN THE ACTG A5357 STUDY
Background: VRC07-523LS is a broadly neutralizing anti-HIV-1 envelope monoclonal antibody under investigation in combination with LA-cabotegravir for maintenance of HIV-1 suppression in the AIDS Clinical Trials Group (ACTG) A5357 study. Eligibility for A5357 required susceptibility to VRC07-523LS, defined as half-maximal inhibitory concentration (IC50) ≤ 0.25 μg/mL and a maximum percent inhibition (MPI) > 98% on…